English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Typhoid is responsible for an estimated 11-21 million cases of febrile illness with 117,000 to 161,000 deaths worldwide annually [1].Though actual incidence rate of enteric fever in Indian population is lacking, three communitybased studies conducted in India between 1995 and 2006 estimated the incidence of culture confirmed typhoid at 377 (178–801) per 100,000 person-years, with the highest incidence in early childhood [2]. The increasing rates of drug resistant S. typhi,including Extremelydrug resistant (XDR) S. typhi, in South Asia is also a cause for concern [3]. World health organization (WHO) recommends programmatic use of typhoid conjugate vaccine to prevent the incidence of typhoid and reduce antimicrobial resistance. This use of vaccine must go hand in hand with other preventive measures, such as improved sanitation, hygiene and access to safe drinking water for a visible reduction in burden of typhoid fever [4]. In India, the typhoid vaccine is not yet a part of the national immunization schedule. The high burden of typhoid in India, the increasing rates of drug-resistant typhoid and the availability of effective conjugate vaccines is likely to alter the vaccination scenario for typhoid.

Typhoid Conjugate Vaccine: Is It Time for It To Be in the National Immunization Schedule?